Evidence-Based Review of the Management of Hepatic Hydrothorax

Amita Singh    Abubakr Bajwa    Adil Shujaat
Department of Pulmonary and Critical Care, UF College of Medicine at Jacksonville, Jacksonville, Fla., USA

Introduction

Hepatic hydrothorax (HH) is defined as transudative pleural effusion associated with portal hypertension without any cardiac, pulmonary and pleural disease. The presence of portal hypertension but not end-stage liver disease is a requirement for the development of HH [1]. The amount of pleural fluid is usually greater than 500 ml. HH is not a common complication of end-stage liver disease. A large amount of ascitic fluid can be easily tolerated by patients but even 1–2 liters of pleural fluid can produce significant symptoms of dyspnea due to reduced capacity of the thoracic cavity as compared to the abdominal cavity. Therefore, the management of HH becomes challenging in patients with portal hypertension. Different treatment options for HH including medical management with diuretics, thoracentesis, and pleurodesis with or without repair of diaphragmatic defects have been proposed in the literature. The aim of the present review is to discuss the pathophysiology, clinical manifestations and diagnosis of this disorder and to present an evidence-based review of the management of HH. The search engines that were used to obtain data were PubMed and Google Scholar (table 1) including case reports, original studies and a meta-analysis in English language only.
lymphatic leakage from the thoracic duct resulting in decreased colloid osmotic pressure

sided and 3% can be bilateral typically bilateral. However, 17.5% of effusions can be left compared to pleural effusions of cardiac origin which are right sided accounting for about 79.5% of all effusions as Pleural effusions in cirrhotic patients are predominantly associated with SBP

nitis (SBP). In a prospective study, the incidence of SBEM was found to be 13% [11], similar to the 15–20% incidence of SBP in hospitalized patients with cirrhosis [12, 13]. Interestingly, up to 40% of SBEM patients are not associated with SBP [11].

Pathophysiology

The underlying mechanisms for HH are similar to those leading to fluid accumulation and ascites in portal hypertension. Portal hypertension and splanchic vasodilation plays an important role in the formation of ascites. Several mechanisms have been postulated for the development of HH in patients with liver cirrhosis. These include the transfer of the peritoneal fluid into the pleural space via diaphragmatic defects [14], hypoalbuminemia resulting in decreased colloid osmotic pressure [15] and lymphatic leakage from the thoracic duct [16]. The direct passage of fluid from the peritoneal to the pleural cavity through diaphragmatic defects has been proposed as the most accepted mechanism explaining most cases of HH.

This has been observed in many studies [17–19]. This mechanism was first suggested by Lieberman et al. [20] following the observation of a pneumothorax after injection of air into the peritoneal cavity. When air is infused intraperitoneally in patients with HH, it can be seen on the chest X-ray performed 48 h later as lucency above the right side of the diaphragm. Other studies have also suggested the rapid movement of air, dyes or radiolabeled material from the peritoneal cavity into the pleural space as the mechanism for HH [21].

Huang et al. [22] classified the diaphragmatic defects thoracoscopically into four morphological types:

- Type 1: no obvious defect
- Type 2: blebs lying in the diaphragm
- Type 3: broken defects (fenestrations) in the diaphragm
- Type 4: multiple gaps in the diaphragm

The microscopic examination of these defects reveals discontinuities in the collagen bundles of the tendinous portion of the diaphragm [20]. Most of these defects occur on the right side because of the close anatomical proximity of the liver with the diaphragm. The negative intrathoracic pressure and the close proximity of the liver with diaphragm, which acts a piston, cause the unidirectional movement of fluid from the abdominal to the pleural cavity. This unidirectional valvular mechanism of development of HH has been confirmed with various studies using nuclear imaging with $^{99m}$Tc-human albumin or $^{99m}$Tc-sulfur colloid or dye. These studies have demonstrated the passage of these radioisotopes from the abdominal to the pleural cavity in the first 24 h after administration [23, 24]. Even though the diaphragmatic defects can be seen in 20% of noncirrhotic patients, pneumothorax rarely develops after laparoscopic procedures [25]. This is because the pressure gradient between the peritoneal and the pleural cavity is altered in patients with ascites; the increased intra-abdominal pressure and diaphragmatic thinning due to malnutrition in cirrhotic patients leads to enlargement of these defects with subsequent unidirectional passage of ascitic fluid into the chest. Herniation of the peritoneum into the pleural space can develop because of the increase in gaps between the muscle fibers of the diaphragm with increased intra-abdominal pressure. These herniations are known as pleuropertitoneal blebs which may rupture, facilitating the fluid passage. In patients without ascites, the mechanism of HH formation is similar. In these patients, virtually all ascitic fluid rapidly crosses the diaphragm into the pleural space. Ascites develops in these patients when the formation of ascitic fluid exceeds the lymphatic absorption and transfer into the pleural space.

<table>
<thead>
<tr>
<th>Table 1. Search engines used for literature review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Search engine</td>
</tr>
<tr>
<td>Search words</td>
</tr>
</tbody>
</table>
SBEM occurs due to the direct spread of infection from the peritoneal space through diaphragmatic defects. However, SBEM has also been reported in patients without ascites, supporting the hypothesis that hematogenous spread of enteral microorganisms to the pleural space is also responsible for the development of SBEM [11, 26]. Enterobacteriaceae (Escherichia coli and Klebsiella pneumoniae), streptococcus species and enterococcus species are the most frequent flora seen in SBEM.

Clinical Presentation

The clinical presentation is usually dominated by signs and symptoms of cirrhosis and portal hypertension, i.e. ascites, spider naevi, asterixis, hepatosplenomegaly, caput medusa and hepatic encephalopathy. Most of the effusions are right sided but a few patients can present with left-sided or bilateral effusions [10]. Patients may be asymptomatic in whom pleural effusion can be an incidental finding on chest imaging performed for other reasons [27] or they may have pulmonary symptoms of shortness of breath, cough, hypoxemia or respiratory failure associated with large pleural effusions. These clinical features depend on various factors like the volume of the pleural fluid, the rapidity of accumulation of the pleural fluid and the presence of associated cardiopulmonary disease. In a review of 24 cases in a 1-year period, most of the effusions were small to moderate in size, and only 6% had large effusions occupying more than half a hemithorax [28]. Sometimes cirrhotic patients present primarily with pulmonary complaints related to hydrothorax [29–32]. Isolated hydrothorax without any clinical ascites has been reported in about 20% of patients [33], but when both computed tomography (CT) and ultrasonography were used, it was found in 7% of the patients [34].

A case of acute tension hydrothorax leading to respiratory failure due to sudden rupture of a large pleuropertitoneal bleb secondary to increased intra-abdominal pressure was also reported [35]. Large effusions have the potential of causing cardiac tamponade with profound systemic hypotension that may require immediate intervention [36]. SBEM should always be suspected when patients develop fever, pleuritic chest pain or encephalopathy.

Diagnosis

HH is confirmed in a patient with portal hypertension and ascites who present with pleural effusion after excluding any primary pulmonary, cardiac or pleural disease. Effusions can be seen on chest X-ray or on other imaging studies like ultrasonography and CT of the chest or abdomen.

The initial evaluation of effusion should be the analysis of pleural fluid to identify the nature of the fluid and to rule out any other causes of effusions like infections, including SBEM, inflammation or malignancy. In a study of 60 cirrhotic patients with pleural effusions [37], 42 patients (70%) were found to have pleural fluid analysis compatible with hydrothorax. The remaining 18 patients (30%) had a diagnosis other than HH like SBEM in 9 (15%), tuberculosis in 2, adenocarcinoma in 2 and para-pneumonic empyema in 2 patients; 3 were undiagnosed exudates. Also, 64% of the left-sided effusions were found to be complicated compared with 20% right-sided complicated effusions. Hence, thoracentesis with analysis of pleural fluid is a must in cirrhotic patients with pleural effusions. Also, left-sided pleural effusions should not be assumed to be uncomplicated HH, as also shown in previous studies [38]. Pleural fluid analysis should include protein, albumin and lactate dehydrogenase (LDH) levels, cell count, gram stain and culture examination. HH is transudative in nature. In a retrospective study of 41 HH patients, solitary HH was found in 33 patients [34]. Of these 33 patients, 31 (94%) were transudates. Sixteen (48%) had a total protein level <1.5 g/dl in the pleural fluid, none had a serum albumin value <1.5 g/dl, microbiologic cultures were negative in 31 patients, and in 30 patients, cytology was negative for any malignant cells. The median pleural fluid pH was 7.49, total protein was 1.5 g/dl and LDH was 65 IU/l. The median pleural fluid/solvent ratio and median pleural fluid LDH/upper limit of normal LDH ratio were 0.25 and 0.27, respectively. The absolute neutrophil count (ANC) was <250/μl. Only a single patient had a protein discordant exudate despite 83% of patients receiving diuretics. Authors concluded that diuretic therapy has a minimal effect in changing the pleural fluid chemistry in HH. However, when HH is an exude probably because of diuretics, the serum/pleural fluid albumin ratio should be calculated, and a value <0.6 is classified as transudate [39]. The characteristics of the pleural fluid in HH are listed in table 2. As in transudative pleural effusion, total protein is <2.5 g/dl [40] in HH with low LDH and glucose levels similar to the serum glucose level [9]. The serum/pleural fluid albumin gradient is usually >1.1 g/dl, similar to that of ascites resulting from portal hypertension, although this has not been studied extensively.

Other tests that should be considered with respect to the pleural fluid include pH, triglycerides, adenosine deaminase, glucose levels and LDH.
aminase and PCR for tuberculosis, amylase and cytology, to exclude empyema, chylothorax, tuberculosis, pancreatitis and malignancy, respectively, in patients in whom another diagnosis is suspected.

In cases of SBEM, pleural fluid will have a high ANC level of >250 cells/mm³ with positive fluid culture or ANC >500 cells/mm³ with negative fluid culture without any evidence of pneumonia on chest X-ray, evidence of pleural effusion before an infectious episode and transudate characteristics of the fluid during infection [26]. Inoculation of pleural fluid in blood culture bottle at bedside increases the sensitivity from 33 to 77% [11]. Patients who develop SBEM have lower levels of pleural fluid total protein of <1 mg/dl, low pleural fluid C3 and a higher Child-Pugh-Turcotte (CTP) score (table 3a, b) than those who do not develop SBEM [40]. SBP has also been recognized as a risk factor for SBEM [7].

Although the diagnosis of HH may require exclusion of alternative diagnoses in some cases, demonstration of a peritoneal-pleural communication is not necessary in clinical practice unless surgical repair is being contemplated. The test to confirm the communication between the pleural and the peritoneal space is scintigraphy which involves the intraperitoneal administration of a radiisotope and the migration of the radioisotope into the pleural cavity after few hours [41–43]. Transdiaphragmatic movement of ascitic fluid into the pleural cavity using contrast-enhanced ultrasonography with the contrast agent Sonazoid has also been reported [44]. Magnetic resonance imaging has also been used to detect diaphragmatic defects in HH [45]. These studies are not necessary to diagnose HH unless HH exists in the absence of ascites [23, 46] or there is a plan to close the communications between the peritoneal and pleural space by video-assisted thoracoscopy.

**Table 2. Characteristics of pleural fluid in HH**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polymorphonuclear count</td>
<td>&lt;250 cells/mm³</td>
</tr>
<tr>
<td>Total protein</td>
<td>&lt;2.5 g/dl</td>
</tr>
<tr>
<td>Pleural fluid total protein/serum total protein ratio</td>
<td>&lt;0.5</td>
</tr>
<tr>
<td>Pleural fluid LDH/serum LDH</td>
<td>&lt;0.6</td>
</tr>
<tr>
<td>Serum pleural to fluid albumin gradient</td>
<td>&gt;1.1 g/dl</td>
</tr>
<tr>
<td>Glucose level similar to that of serum</td>
<td>pH 7.4 – 7.55</td>
</tr>
</tbody>
</table>

**Table 3a. CTP scoring**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Encephalopathy</td>
<td>altered mood or confusion (2 points)</td>
<td>inappropriate behavior, impeding stupor, somnolence (2 points)</td>
<td>markedly confused, stuporous but arousable (3 points)</td>
<td>comatose/unresponsive (3 points)</td>
</tr>
<tr>
<td>Ascites</td>
<td>Absent (1 point)</td>
<td>Slight (2 points)</td>
<td>Moderate (3 points)</td>
<td></td>
</tr>
<tr>
<td>Bilirubin</td>
<td>&lt;2 mg/dl (1 point)</td>
<td>2 – 3 mg/dl (2 points)</td>
<td>&gt;3 mg/dl (3 points)</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>&gt;3.5 g/dl (1 point)</td>
<td>2.8 – 3.5 g/dl (2 points)</td>
<td>&lt;2.8 g/dl (3 points)</td>
<td></td>
</tr>
<tr>
<td>Prothrombin</td>
<td>&lt;4 s above control/INR &lt;1.7 (1 point)</td>
<td>4 – 6 s above control/INR 1.7 – 2.3 (2 points)</td>
<td>&gt;6 s above control/INR &gt;2.3 (3 points)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3b. CTP class**

<table>
<thead>
<tr>
<th>Points</th>
<th>Class</th>
<th>1-year survival</th>
<th>2-year survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 – 6</td>
<td>A</td>
<td>100%</td>
<td>85%</td>
</tr>
<tr>
<td>7 – 9</td>
<td>B</td>
<td>81%</td>
<td>57%</td>
</tr>
<tr>
<td>10 – 14</td>
<td>C</td>
<td>45%</td>
<td>35%</td>
</tr>
</tbody>
</table>

**Table 4. Approach to the treatment of HH**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce the formation of ascitic fluid</td>
<td>Decrease salt and fluid intake</td>
</tr>
<tr>
<td>Decrease salt and fluid intake</td>
<td>Diuretics</td>
</tr>
<tr>
<td>Diuretics</td>
<td>Somatostatin</td>
</tr>
<tr>
<td>Somatostatin</td>
<td>Terlipressin</td>
</tr>
<tr>
<td>Terlipressin</td>
<td>TIPS</td>
</tr>
<tr>
<td>TIPS</td>
<td>Liver transplant</td>
</tr>
<tr>
<td>Prevent the transfer of ascitic fluid across the diaphragm</td>
<td>Paracentesis</td>
</tr>
<tr>
<td>Paracentesis</td>
<td>Repair of diaphragmatic defects</td>
</tr>
<tr>
<td>Repair of diaphragmatic defects</td>
<td>CPAP</td>
</tr>
<tr>
<td>Drain the pleural space</td>
<td>Repeated thoracentesis</td>
</tr>
<tr>
<td>Repeated thoracentesis</td>
<td>Indwelling pleural catheter</td>
</tr>
<tr>
<td>Indwelling pleural catheter</td>
<td>Pleurovenous shunt</td>
</tr>
<tr>
<td>Obliterate the pleural space (pleurodesis)</td>
<td>Instillation of sclerosant through the chest tube</td>
</tr>
<tr>
<td>Instillation of sclerosant through the chest tube</td>
<td>Talc poudrage</td>
</tr>
<tr>
<td>Talc poudrage</td>
<td>VATS and pleurodesis*</td>
</tr>
<tr>
<td>VATS and pleurodesis*</td>
<td>1) Chemical</td>
</tr>
<tr>
<td>1) Chemical</td>
<td>2) Mechanical</td>
</tr>
</tbody>
</table>

* May be combined with repair of diaphragmatic defects.
An echocardiography is generally performed to rule any cardiac causes of pleural effusions. In a study of 41 HH patients, an intrapulmonary shunt was detected in 78% (18 of 23) patients on contrast-enhanced echocardiography with agitated saline. There was also a high prevalence of diastolic dysfunction and left atrial enlargement in HH patients. However, the study did not mention how these patients were distinguished from left heart failure. The high prevalence of diastolic dysfunction can suggest that heart failure might have contributed to the development of pleural effusions [34]. The increased neurohormonal activity associated with cirrhosis leading to cardiac hypertrophy along with impaired relaxation has been speculated as the reason for diastolic dysfunction in cirrhotic patients [47, 48].

In addition to the above, basic metabolic panel, hepatic panel, brain natriuretic peptide and prothrombin time should be obtained in appropriate clinical setting. CT of the chest may be needed to exclude pulmonary, mediastinal or pleural causes or malignancies. The stepwise approach to the diagnosis of HH is shown in figure 1.

**Management**

HH is an example of the porous diaphragm syndrome [14]. Portal hypertension results in the formation of ascitic fluid which moves across defects in the diaphragm and accumulates in the pleural space. Consequently, the treatment approach to HH consists of measures to reduce the formation of ascitic fluid, prevent the movement of ascitic fluid across the diaphragm, and drain or obliterate the pleural space. Table 4 shows the various therapeutic options for HH.

Approximately 21–26% of HH cases are refractory to salt and fluid restriction and diuretics [4, 40] and warrant consideration of additional treatment measures. Ideally,
liver transplantation is the best treatment option for these patients [49, 50]; however, most of the patients are not candidates [51] and most of those who are eligible die while waiting for a transplant [52, 53]. Treatment measures other than liver transplantation may not only provide relief from dyspnea but also improve patient survival and serve as a bridge to liver transplantation. In a study of 52 HH patients [54], resolution of hydrothorax for at least 3 months was reported in 37.5% of patients with chemical pleurodesis and in 42.9% after surgical intervention, with an overall success rate of 50%. The median survival of patients with intervention success (22.5 months) was significantly longer than in those with intervention failure (5.4 months) and supportive care (6.3 months). The advantages and disadvantages of different therapeutic options are shown in table 5.

### Table 5. Advantages and disadvantages of the different treatment modalities for HH

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical management</td>
<td>- Cheap</td>
<td>- High noncompliance rate</td>
</tr>
<tr>
<td></td>
<td>- Noninvasive</td>
<td>- Risk of acute kidney injury and renal failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Ineffective in refractory HH</td>
</tr>
<tr>
<td>Thoracentesis</td>
<td>- Relief of symptoms</td>
<td>- Frequent requirement</td>
</tr>
<tr>
<td></td>
<td>- Allows pleural fluid analysis to rule out other</td>
<td>- Complications like pneumothorax, hemothorax,</td>
</tr>
<tr>
<td></td>
<td>diagnoses like SBEM</td>
<td>reexpansion pulmonary edema</td>
</tr>
<tr>
<td>TIPS</td>
<td>- Bridge to liver transplant</td>
<td>- Post-TIPS hepatic encephalopathy</td>
</tr>
<tr>
<td></td>
<td>- Success rate of 70–80%</td>
<td>- Shunt occlusion and thrombosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Poor survival in MELD &gt;15, CTP class C and high</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pre-TIPS creatinine of &gt;2 mg/dl</td>
</tr>
<tr>
<td>Pleurodesis</td>
<td>- Repair of diaphragmatic defects can be performed</td>
<td>- Repeated procedures are needed</td>
</tr>
<tr>
<td></td>
<td>- Success can be increased with CPAP, somatostatin</td>
<td>- General anesthesia needed for VATS</td>
</tr>
<tr>
<td></td>
<td>- Considered in patients when TIPS is contraindicated</td>
<td>- Complications like empyema, sepsis, septic shock</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Increase bleeding risk with mechanical pleurodesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Cannot be performed in trapped lung</td>
</tr>
<tr>
<td>Surgical repair of diaphragmatic defects</td>
<td>- Increase success of pleurodesis</td>
<td>- Not always visualized</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Invasive</td>
</tr>
<tr>
<td>Liver transplant</td>
<td>- Most effective management option</td>
<td>- Long waiting time</td>
</tr>
</tbody>
</table>

Reduce the Formation of Ascitic Fluid

**Medical Management**

The primary goal of HH treatment is to achieve a negative sodium balance by restricting sodium intake and pharmacological therapy using diuretics [55]. Sodium intake in the diet should be <2,000 mg/day. A combination of loop diuretics (furosemide) and Aldactone receptor antagonist (spironolactone) is used to achieve a renal excretion of at least 120 mEq sodium/day [56].

Diuretics can be increased in a stepwise manner by doubling the dose every 5 days if there is no response to treatment, and noncompliance with diet and medications have been excluded. Maximum doses of spironolactone and furosemide are up to 400 and 160 mg/day, respectively [57, 58]. Patients who do not respond to medical therapy are considered to have a refractory hydrothorax. It is a clinical challenge to manage refractory hydrothorax as most of these patients have associated renal dysfunction along with impaired liver function. Aggressive diuresis is usually complicated by renal insufficiency and electrolyte imbalance and is poorly tolerated in these patients. In a retrospective study of 405 patients with cirrhosis admitted over a 5-year period, 7 of 27 (25.9%) HH patients were refractory to medical treatment [4]. In another prospective study of 60 cirrhotic patients, 13 (21.7%) HH patients were considered refractory [40].

A recent case report showed that intravenous terlipressin, which is known to be beneficial in the hepatorenal syndrome, might also be effective in HH [59]. Intravenous octreotide has also been successful for HH treatment [60]. A case of refractory HH, which resolved after...
adding the α-adrenergic agonist midodrine to octreotide, has also been reported [61]. Octreotide can potentiate the beneficial hemodynamic and renal effects of midodrine in decompensated cirrhosis [62]. The hypothesis behind the use of these agents is to reduce splanchic blood flow thereby decreasing peritoneal and pleural fluid accumulation. However, there are not enough data to support the routine use of these drugs in the management of HH. Moreover, such treatment may be costly and impractical on an outpatient basis because of the intravenous route of administration.

Transjugular Intrahepatic Portosystemic Shunt

Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that creates an anastomosis between the portal and the hepatic vein. It decompresses the splanchic vascular bed, thereby decreasing portal venous pressure. The efficacy of TIPS in HH has been reported in several retrospective nonrandomized studies and case reports [33, 63–70].

Table 6 compares and summarizes the results of these studies. A total of 332 patients were included in these studies. The overall response rate, which was defined as complete or partial response with respect to the resolution of the hydrothorax, an improvement in respiratory symptoms and a decrease in the frequency ofthetaenesis, was found to be 73.71%, with a range of 58–82%. The mean complete and partial response rates were 55.9 and 24.6%, respectively. Spencer et al. [68] showed that the complete resolution of the hydrothorax on a radiograph is not required for a patient to be free of symptoms.

The major complication of the TIPS procedure is the development or worsening of hepatic encephalopathy. Compounds that require hepatic detoxification in the portal circulation bypass the liver through TIPS and enter the systemic circulation causing post-TIPS encephalopathy. In the largest series evaluating TIPS in HH done by Dhanasekaran et al. [70], hepatic encephalopathy developed in 15% of the patients. The other complications included infection in 8.2%; procedure-related bleeding in 6.8%, acute renal failure in 2.7% and the acute respiratory distress syndrome in 2.7%. The study did not specify the criteria for the diagnosis of the acute respiratory distress syndrome. Given the high prevalence of diastolic heart failure in HH patients [34], these patients might have developed pulmonary edema secondary to heart failure due to a sudden increase in preload after TIPS.

The incidence of hepatic encephalopathy ranged anywhere between 5 and 50% in different studies, with an average of 26.7% [33, 65–70]. This could be because of the retrospective nature of these studies making it difficult to assess the grade of encephalopathy after TIPS. Shunt occlusion or thrombosis is also one of the late complications of the TIPS procedure causing reaccumulation of pleural fluid and ascites. The patency of covered stents seems to be better than that of uncovered stents. In a prospective randomized study that compared the patency rates of covered and uncovered stents, the patency rate was found to be better with covered stents (76%) then with uncovered stents (36%) [71].

The average 30-day mortality was around 18.6%. The factors associated with mortality after TIPS for HH are age >60 years, CTP class C, high pre-TIPS model for end-stage liver disease (MELD) score >15 (table 7) and high pre-TIPS creatinine levels >2 mg/dl [33, 68, 70]. The 1-year survival rates mentioned in three studies ranged from 41 to 64%, with a mean of 52.3% [33, 69, 70]. The highest survival rate was seen by Siegerstetter et al. [33]. The clinical response, age <60 years and pre-TIPS MELD score were significantly correlated with survival [33, 70].

TIPS does not improve the overall prognosis of patients with end-stage liver disease. In carefully selected patients with MELD score <15, CTP A or B and age <60 years, TIPS can be an effective treatment of refractory hydrothorax and can be used as a bridge to liver transplantation. The absolute contraindications to TIPS include cardiac conditions that may worsen after the procedure like congestive heart failure (CHF), severe tricuspid regurgitation and severe pulmonary hypertension with mean pulmonary pressures >45 mm Hg [72]. In patients with high predicted 30-day mortality rates with MELD >15 and CTP class C, TIPS should only be performed in the absence of other options. Patients with high MELD score have severe hepatic dysfunction; performing TIPS in these patients could precipitate liver failure due to shunting of blood away from the liver leading to hepatic ischemia. TIPS is contraindicated in patients with hepatic encephalopathy only if hepatic encephalopathy is uncontrollable with medical therapy. Only 5% of cases require occlusion of TIPS or a reduction in the TIPS caliber to control encephalopathy. Relative contraindications to TIPS include portal venous obstruction, large hepatic tumors, extensive polycystic liver disease, hepatic vein obstruction, severe coagulopathy (INR >5) and thrombocytopenia <20,000/cm². Patients with significant coagulopathy may be able to undergo TIPS following treatment with clotting factors or platelets [72].
Table 6. Results of TIPS in refractory HH

<table>
<thead>
<tr>
<th>First author</th>
<th>Total n</th>
<th>Age years</th>
<th>Sex</th>
<th>Success rate</th>
<th>Success defined</th>
<th>TIPS patency</th>
<th>HE</th>
<th>Follow-up duration</th>
<th>30-day mortality %</th>
<th>1-year probable survival %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strauss [64]</td>
<td>5</td>
<td>CTP: C 5</td>
<td></td>
<td>Overall: 80%</td>
<td>CR: 40%</td>
<td>Occlusion:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 40%</td>
<td>60% (3/5)</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NR: 20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gordon [65]</td>
<td>24</td>
<td>CTP: B 5</td>
<td>58.2</td>
<td>M 14 F 10</td>
<td>Overall: 79%</td>
<td>TIPS</td>
<td></td>
<td>7.2 months</td>
<td>20.8a</td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 58.3%</td>
<td>patency:</td>
<td></td>
<td>(0.25–49 months)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 20.8%</td>
<td>87.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occlusion/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>stenosis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3/24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffries [66]</td>
<td>12</td>
<td>CTP: A 1</td>
<td>54</td>
<td>(41–72)</td>
<td>M 4 F 8</td>
<td>Overall: 58%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 41.6%</td>
<td>CR: resolution</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 16.6%</td>
<td>of hydrothorax</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>or resp. symptoms with</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>reduction in pleural fluid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: reduced frequency of thoracentesis with improved resp. symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>patency:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>87.5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occlusion/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>stenosis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3/12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chalasani [67]</td>
<td>129</td>
<td>24-HH CTP: B 30% C 70%</td>
<td>54.8±</td>
<td>M 70 F 30</td>
<td>Overall: 58%</td>
<td>CR: improvement in resp. status with no further thoracentesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: resolution of hydrothorax or resp. symptoms with reduction in pleural fluid PR: reduced frequency of thoracentesis with improved resp. symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: reduced frequency of thoracentesis with improved resp. symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HE: 7/12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Siegerstetter [33]</td>
<td>40</td>
<td>CTP: B 24 C 16</td>
<td>54</td>
<td>(31–70)</td>
<td>M 21 F 19</td>
<td>Overall: 82%</td>
<td>CR: lack of pleural effusion PR: lack of thoracentesis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 71%</td>
<td>TIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 12%</td>
<td>patency:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20/40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HE: 5%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2/40)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spencer [68]</td>
<td>21</td>
<td>CTP: B 7</td>
<td>56</td>
<td>(34–74)</td>
<td>M 12 F 9</td>
<td>Overall: 74%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 64%</td>
<td>CR: symptom and effusion resolution PR: improved symptom and effusion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 10%</td>
<td>TIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>patency:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24.7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occlusion:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15.1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HE: 15.1%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(range 1–4,308)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>759 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dhanasekaran[70]</td>
<td>73</td>
<td>Pre-TIPS MELD: &lt;15: 32.8% &gt;15: 67.2%</td>
<td>55.62</td>
<td>M 40 F 33</td>
<td>Overall: 75%</td>
<td>CR: absence of symptoms no further thoracentesis. PR: improvement in symptoms with decreased need for thoracentesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CR: 60%</td>
<td>TIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 15%</td>
<td>patency:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(at 6 months)</td>
<td>24.7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Occlusion/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>stenosis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7/33</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>332</td>
<td></td>
<td></td>
<td>Overall: 73.71</td>
<td>CR: 55.9%</td>
<td>TIPS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PR: 24.6%</td>
<td>patency:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>68% (18.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CR = Complete response; HE = hepatic encephalopathy; L = left pleural effusion; PR = partial response; R = right pleural effusion.
45-day mortality.
*aCumulative survival over entire course of study.
Liver Transplant
Liver transplant is the treatment of HH and is indicated in refractory hydrothorax, hydrothorax with poor liver function (MELD >15) and after a SBEM episode. In a study by Xioli et al. [73], postoperative mortality, long-term survival, days of mechanical ventilation after surgery and transfusion requirements were similar in the hydrothorax group (n=28) and in the control group (n=56) who underwent orthotopic liver transplantation for reasons other than HH. There was no difference in survival between patients with and without SBEM. The mean survival of patients transplanted because of HH was 114 months, with 82% patients were alive at 1 year and 70% at 5 years. Pleural effusion persisted in 9 patients 1 month after orthotropic liver transplantation but only in 1 patient after 3 months, which was attributed to heart failure.

Similar findings were also observed in another study that compared pre- and posttransplant symptoms and management of patients with HH and end-stage liver disease [74]. Of 11 patients, 73% needed thoracentesis in the pretransplant course, with 55% requiring more than once. None of the patients required thoracentesis in the posttransplant course. When this group of patients was compared with two control groups of 11 patients each (patients with tense ascites with no hydrothorax and patients without ascites), no significant differences were observed in terms of duration of mechanical ventilation, intensive care unit stay, inhospital stay, sepsis and early postoperative death. One-year survival was also similar in all groups.

Presence of HH does not lead to more postoperative complications, and long-term survival is similar to other indications of liver transplantation. Liver transplantation is an excellent therapeutic option for patients with refractory HH. The challenge is to determine the appropriate treatment to bridge them to liver transplantation when TIPS is not a good option. In such patients, other treatment modalities like pleurodesis with or without repair of diaphragmatic defects or an indwelling pleural catheter can be considered. Pleurodesis is not considered a contraindication to liver transplantation.

Liver transplantation has also shown to have good outcome in SBEM. In a small series of 24 patients with SBEM, survival was 100% in all of the 5 patients who underwent transplantation [11]. Though antibiotics, especially third-generation cephalosporins, are required in these patients, SBEM should be considered an indication for orthotopic liver transplant irrespective of SBP.

Prevent the Transfer of Ascitic Fluid across the Diaphragm
Paracentesis
Paracentesis is a simple and well-tolerated procedure and should be attempted in all patients with HH prior to thoracentesis to prevent the rapid accumulation of fluid in the pleural space after thoracentesis due to decreased intrathoracic pressure. Large volume paracentesis can also provide symptomatic relief of dyspnea in patients with HH even before thoracentesis is performed. A study by Angueira and Kadakia [75] demonstrated a statistically significant increase in total lung capacity and functional residual capacity with symptomatic improvement within 2 h of paracentesis with an average fluid removal of 3.5 liters. Another study of 31 cirrhotic patients with acute lung injury on mechanical ventilation reported a decrease in intra-abdominal pressure and an increase in PaO₂/FiO₂ and end-expiratory lung volume without hemodynamic disturbances following paracentesis of an average of 3.6 liters [76].

Peritoneovevesical Shunt
A peritoneovesical shunt known as ALFA pump system is a new investigational technique that has been approved in Europe for the management of ascites but has not yet been approved in the United States [77]. It is implanted subcutaneously and pumps excess peritoneal fluid into the bladder where the patient can eliminate it through normal urination. Reduction in ascites may also decrease HH formation. However, it is still in the experimental stage and has only been used in phase 3 clinical trials so far.

Table 7. MELD score

<table>
<thead>
<tr>
<th>Calculation</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>MELD = 3.78 [ln serum bilirubin (mg/dl)] + 11.2 [ln INR] + 9.57 [ln serum creatinine (mg/dl)] + 6.43</td>
<td>3-month mortality based on MELD score:</td>
</tr>
<tr>
<td>≥40: 71.3% mortality</td>
<td></td>
</tr>
<tr>
<td>30–39: 52.6% mortality</td>
<td></td>
</tr>
<tr>
<td>20–29: 19.6% mortality</td>
<td></td>
</tr>
<tr>
<td>10–19: 6.0% mortality</td>
<td></td>
</tr>
<tr>
<td>&lt;9: 1.9% mortality</td>
<td></td>
</tr>
</tbody>
</table>

Hepatic Hydrothorax

<ref>Table 7. MELD score</ref>

Respiration 2013;86:155–173
DOI 10.1159/000346996
163
Repair of Diaphragmatic Defects

Repair of the diaphragmatic defects to reduce the flux of fluid from the peritoneal to the pleural cavity has been shown to be effective in recurrent HH. These diaphragmatic defects can be visualized thoracoscopically or with the use of dye or pneumoperitoneum. Ibi et al. [78] reported 2 cases of refractory HH that were successfully treated with repair of diaphragmatic defects with sutures, biological glue and mesh during video-assisted thoracoscopic surgery (VATS). The defects were explored using dye and pneumoperitoneum. There was no recurrence of hydrothorax in both cases at the 1-year follow-up. In a surgical series of 10 patients, Huang et al. [79] reported successful control of HH with thoracoscopic pleural mesh onlay reinforcement to repair the diaphragmatic fenestrations. There was no recurrence in any patient after a mean follow-up of 7.7 months. Two patients died of hemorrhage from esophageal varices 2 months postoperatively.

Repair of the defects has also been combined with pleurodesis during VATS to increase the success of the procedure. The success rate increased from 47.6 to 60% after repair of the diaphragmatic defects in a study of 18 patients with refractory HH [80]. However, these defects cannot be visualized in all patients. Luh and Chen [81] visualized diaphragmatic defects in only 2 of 12 (16.7%) patients, which were repaired with sutures. Similarly, in other studies, diaphragmatic defects were visualized in 12 and 22.2% of the cases, respectively [82, 83], and in some series, diaphragmatic defects could not be visualized at all during VATS [84].

Although this approach appears encouraging, it is limited by the lack of visualization of the diaphragmatic defects. However, if a patient is taken for VATS pleurodesis then an attempt to visualize the diaphragmatic fenestrations and repair, if possible, should be considered to increase the successful outcome of pleurodesis.

Continuous Positive Airway Pressure

Continuous positive airway pressure (CPAP) decreases the negative pressure in the thoracic cavity, thereby decreasing the pressure gradient between peritoneal and pleural cavities and thus preventing the flux of fluid from the abdomen to the pleural space. A case of resistant HH with marked improvement following nasal CPAP treatment during sleep has been reported [85]. In one study, CPAP was combined with pleurodesis to improve the success rate by increasing positive intrathoracic pressure and reversing the peritoneal-pleural pressure gradient. This reversing of the pressure gradient encourages the backward flow of fluid from the pleural to the peritoneal space, thereby allowing more time for the pleural surfaces to be dry to achieve pleurodesis [86]. However, further large studies are needed to validate the use of CPAP solely for the management of refractory HH, but a combination of CPAP with other techniques like pleurodesis appears promising theoretically. Also, increased risk of aspiration with the use of CPAP in the setting of hepatic encephalopathy should be kept in mind.

Drain the Pleural Space

Repeated Thoracentesis

Patients with symptomatic refractory hydrothorax require thoracentesis for relief of dyspnea symptoms. The procedure is generally well tolerated, however, if thoracentesis is required every 2–3 weeks inspite of maximal medical therapy then alternative treatments should be considered, as the procedure-related complications, including pneumothorax and hemothorax, increase with the increased frequency of procedures. As mentioned before, when ascites is present, paracentesis should always be performed before thoracentesis to minimize the recurrence of hydrothorax immediately after thoracentesis.

There is no consensus for the maximal volume of pleural fluid to be drained in a single thoracentesis procedure. There have been postulations to drain less than or equal to 2 liters of pleural fluid to prevent reexpansion pulmonary edema, but no randomized controlled studies have been conducted to determine the maximum amount of fluid that can be drained in a single setting. Large volume thoracentesis (>1–6.55 liters) in a prospective study showed that of 185 patients submitted to thoracentesis, only 1 patient (0.5%) experienced edema with clinical manifestations, and 4 (2.2%) developed compatible radiographic abnormalities. The clinical reexpansion pulmonary edema after large-volume thoracentesis was independent of the volume of fluid removed [87]. However, pleural manometry was routinely performed and the procedure was terminated if pleural pressures dropped to −20 cm H2O or the patient developed chest discomfort. The development of chest discomfort that has been correlated with a reduction in pleural pressure should be a sign to terminate thoracentesis [88].

Coagulopathy should not be considered as a contraindication to thoracentesis and paracentesis. A retrospective study of 608 patients undergoing thoracentesis and paracentesis did not show any increased bleeding in patients with mild-to-moderate coagulopathy with either

Respiration 2013;86:155–173
DOI: 10.1159/000346996
Singh/Bajwa/Shujaat
prothrombin time or partial thromboplastin time up to twice the midpoint normal range, or a platelet count of 50–99,000/µl; authors concluded that prophylactic plasma or platelet transfusions are not necessary. However, patients with markedly elevated serum creatinine levels >6.0 mg/dl had a significantly greater average hemoglobin loss of >2 g/dl than patients with normal serum creatinine levels. Overall, red cell transfusions were required only in 0.2% of events [89].

**Chest Tube**

A chest tube should not be placed in HH patients because high chest tube output and massive loss of fluid can lead to renal dysfunction and electrolyte disturbances [89]. Because of the rapid reaccumulation of fluid in the pleural space as well as the high output, removal of the chest tube becomes difficult once it is placed.

A retrospective review of 17 patients (admitted over a 10-year period) with HH and placement of a chest tube showed that 16 of 17 patients had at least one complication and 12 patients had more than one complication. Eleven patients had acute kidney injury, 7 patients had renal dysfunction and 12 patients had more than one complication. The study showed that 80% of patients who received chest tubes for empyema as well as pneumothorax. The study showed that 80% of patients had one or more complications like renal dysfunction, electrolyte imbalances and infection. Mortality was 16% in CTP class B patients and up to 40% among CTP C patients. Deaths while having a chest tube in place were deemed by the authors to be secondary to complications from having it in place, rather than to adverse effects from the tube placement procedure.

Even in cases of SBEM, patients have been treated with antibiotics alone without any requirement of a chest tube. Since chest tube insertion is associated with higher adverse events, as discussed before, and most cases of SBEM respond to antibiotic therapy [11], a chest tube should not be placed in patients with SBEM unless they meet criteria for placing a chest tube like frank pus or pH <7.2.

**Indwelling Pleural Catheter**

Tunneled pleural catheter (PleurX) insertion has been shown to be effective in the management of malignant pleural effusions with symptomatic relief of symptoms and spontaneous pleurodesis in some patients [93]. It is placed under local anesthesia. A case of refractory HH after TIPS that was managed effectively with PleurX catheter insertion had symptomatic improvement, and drainage volume gradually decreased. Spontaneous pleurodesis was achieved without any recurrent pleural effusion at the 6-month follow-up after catheter removal. The catheter was removed due to methicillin-resistant _Staphylococcus aureus_ cellulitis at the insertion site [94].

Chalhoub et al. [95] studied the effectiveness of the PleurX catheter in the management of nonmalignant pleural effusions in a retrospective analysis of patients who underwent PleurX catheter placement for recurrent pleural effusions between 2003 and 2009. Patients were divided into two groups. Group I (n = 23) included patients with nonmalignant pleural effusions and group II (n = 41) included patients with malignant pleural effusions. The diagnoses in group I included CHF (n = 13), HH (n = 8), traumatic bloody (n = 1), and idiopathic exudative effusion (n = 1). The diagnoses in group II included lung cancer (n = 20), breast cancer (n = 11), colon cancer (n = 5), prostate cancer (n = 2), B-cell lymphoma (n = 2) and mesothelioma (n = 1). The time to pleurodesis was higher in group I (110.8 ± 41 days) than in group II (36 ± 12 days). Time to pleurodesis was significantly shorter in HH compared to CHF (73.6 ± 9 vs. 113 ± 36 days, respectively). The authors suggested that the shorter time to pleurodesis in HH patients compared to CHF patients could be related to increased levels of circulating inflammatory mediators in subjects with cirrhosis favoring more rapid pleural symphysis. The mean satisfaction score was similar in both groups. Among subjects who were alive 3 months after catheter removal, none had recurrence of their pleural effusion. There was 1 case of exit-site infection in a patient with HH. There were 3 deaths in the nonmalignant group and 10 deaths in the malignant group. In group I, 3 deaths occurred before the removal of the PleurX catheter. One patient died of myocardial infarction and resulting cardiogenic shock, and 2 patients died of respiratory failure related to hepatic encephalopathy. According to the authors, none of the deaths were related to pleural effusion and catheter-related complications. However, the MELD score or CTP class of patients at baseline were not mentioned in the study.

Another study by Kilburn et al. [96] identified 14 patients who received tunneled pleural catheter placement for the treatment of refractory HH between October 2007 and January 2010. Of 14 cases, 8 patients in whom the PleurX catheter was placed as a bridge to TIPS or transplantation, 5 (62.5%) achieved spontaneous pleurodesis with successful PleurX catheter removal without transplant. Empyema occurred in 2 patients (25%), requiring removal of the catheter in 1 patient.
Though one would expect that the reported complications of repeated fluid removal after placement of a chest tube leading to renal injury should also be seen with the PleurX catheter, the lower incidence of adverse events could be because of intermittent and small amounts of fluid removed each time via the PleurX catheter. However, the long-term requirement of a tunneled pleural catheter in nonmalignant pleural effusions increases the chance of infectious complications. In a small series of patients who received the PleurX catheter for CHF, 2 of 5 patients (40%) developed empyema and 1 patient developed loculations [97]. Even though placement of the PleurX catheter for refractory hydrothorax looks promising, data are limited and further studies are required to compare the effectiveness of the PleurX catheter with other treatment modalities.

**Pleurovenous Shunt**

A few case reports have used a pleurovenous shunt for the management of HH [98, 99]. Artemiou et al. [100] showed the effectiveness of pleurovenous shunts in 12 patients with chronic nonmalignant right-sided pleural effusions. Out of these, 6 had HH. Patients were followed for a period of 13.3 months (1–40 months). All shunts were patent and none of the patients required further treatment for pleural effusion. However, long-term patency and complications of pleurovenous shunts remain currently unknown.

**Obliterate the Pleural Space**

**Pleurodesis**

Pleurodesis is a procedure in which the space between the visceral and parietal pleura is obliterated with the use of an agent that acts as an irritant to cause inflammation on the pleural surfaces. The irritant is administered through a chest tube or during thoracoscopy (medical or VATS). It difficult to achieve pleurodesis because of the dilution of the sclerosing agent and the inability to keep the pleural surfaces juxtaposed due to rapid fluid accumulation in HH because of continuous passage of ascitic fluid from the abdominal cavity.

Table 8 shows the comparison of various studies of pleurodesis for HH management [80–83, 86, 101–105]. The most common sclerosing agent that has been used in different studies is talc. However, a few studies have used tetracycline, OK-432 with minocycline, Vibramycin, povo-iodine and bleomycin [83, 104, 105]. The overall success rate of pleurodesis in different studies, which was defined as radiographic disappearance of pleural fluid and relief of symptoms, has been between 47 and 100%. The average overall success rate was 74.7% and the average recurrence rate, requiring repeated pleurodesis, was 24.5%. The mean duration of chest tube drainage was 8.7 days.

**Chemical Pleurodesis**

Chemical pleurodesis can be done by instillation of a sclerosing agent through a chest tube as well as during medical thoracoscopy. A retrospective Korean study used talc, taurolidine and *Viscum album* in 3, 2 and 6 patients, respectively, for pleurodesis via a chest tube [106]. None of the patients was considered for TIPS as it was not available at the institution where the study was performed. The median MELD score was 16 (9–21). The overall success rate was 72.7% with a recurrence rate of 27%. Patients who achieved success of the treatment showed significantly better outcomes than patients who did not achieve success. Complications included low grade fever and leucocytosis (100%), pneumonia (9.1%), pneumothorax (36.4%), azotemia/acute renal failure (54.6%) and hepatic encephalopathy (36.4%). The procedure-related mortality due to occurrence of acute renal failure was 45.5%.

Only one study used medical thoracoscopy for pleurodesis [104]. However, it is unclear why medical thoracoscopy was done when talc was used as slurry after medical thoracoscopy. Pleurodesis was performed in 23 patients using talc (asbestos free), Vibramycin and povo-iodine with an overall success rate of 75%. All patients were CTP B. The recurrence rate was 20% and mean duration of chest tube drainage was 9.8 ± 2.3 days. However, pleurodesis had to be repeated at least once in all patients (see legend at the bottom of table 8). Moreover, somatostatin was used in all patients to reduce drainage volume and shorten the duration of chest tube removal. As mentioned before, somatostatin reduces splanchic blood flow and the portosystemic pressure gradient, thereby reducing peritoneal and pleural fluid accumulation. Somatostatin was preferred instead of TIPS in the study as per authors somatostatin has few and minor side effects compared to TIPS. Early complications after the procedure included surgical emphysema (18.2%), superficial wound infection (9.1%), mild thoracic pain (4.5%) and a single patient (4.5%) with prehepatic coma 4 days after the procedure that was treated medically. Two (10.5%) patients developed late complications. One patient treated with povo-iodine developed tense ascites. Another patient treated with talc slurry developed tense ascites and hepatic coma at the 3-month follow-up that was treated
Table 8. Results of pleurodesis in refractory HH

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>Procedure</th>
<th>Total n</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Duration of drainage in days</th>
<th>Success rate</th>
<th>Success defined</th>
<th>Mortality at 3 months</th>
<th>Complications</th>
<th>Follow-up duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouroux</td>
<td>1996</td>
<td>France</td>
<td>VATS + TTI Repair of diaphragmatic defects in 6</td>
<td>8</td>
<td>48–66</td>
<td>M 4</td>
<td>7.6 ± 1.75 (5–18) CT removed when drainage &lt;100 ml/48 h</td>
<td>Initial success: 75%</td>
<td>Recs: 2 (25%)</td>
<td>25%</td>
<td>Abnormal liver function (5.9%), pleural effusion (2.7%), pneumonia (1.4%), abdominal pain (1.4%)</td>
<td>7–36 months</td>
</tr>
<tr>
<td>Milanez de Campos</td>
<td>2000</td>
<td>Brazil</td>
<td>VATS + TTI (2 g) Defects seen in 5 pts and sutured in all 5</td>
<td>18</td>
<td>57.6 (26–76)</td>
<td>M 10</td>
<td>12.8 ± 9.5 (4–38) CT removed when drainage &lt;100 ml/48 h</td>
<td>Initial success: 47.6%</td>
<td>Recs: 4 (25%)</td>
<td>38.9%</td>
<td>Fever, mild thoracic pain, empyema (9.5%), pneumonia (4.7%), superficial wound infection (4.7%), persistent air leak (4.7%)</td>
<td>At least 3 months</td>
</tr>
<tr>
<td>Assouad</td>
<td>2003</td>
<td>France</td>
<td>VATS + TTI (6 g) + TS (4–8 g in 20 ml normal saline with 20 ml 1% lidocaine + additional 20 ml NS, clamped for 3 h)</td>
<td>21</td>
<td>59.7 ± 9.9 (42–75)</td>
<td>M 9</td>
<td>TTI 5.8 (2–15) CT removed when drainage &lt;100 ml/24 h</td>
<td>Initial success: TTI 10/13 (77%)</td>
<td>One early Rec cured by TS and 2 late Recs (23%)</td>
<td>14.2%</td>
<td>Absence of pleural fluid on the follow-up CXR Rec: reaccumulation of fluid</td>
<td>29 ±31 months</td>
</tr>
<tr>
<td>Takayama</td>
<td>2004</td>
<td>Japan</td>
<td>VATS + argon beam coagulator + coverage of diaphragm with bioabsorbable prosthesis + 3 ml fibrin glue + 5 KE OK–432 and 100 mg minocycline hydrochloride Repair of diaphragmatic defect in 2 pts</td>
<td>9</td>
<td>65 (55–75)</td>
<td>M 5</td>
<td>4.5 (1–15) CT removed when drainage &lt;100 ml/24 h</td>
<td>Initial success 100%</td>
<td>Recs: 3 (50%)</td>
<td>88.8%a</td>
<td>Disappearance of the pleural effusion and immediate improvement in breathlessness</td>
<td>28 months</td>
</tr>
<tr>
<td>Cerfolio</td>
<td>2006</td>
<td>USA</td>
<td>VATS + TTI (2.5 g) + repair of defects in 5 pts</td>
<td>41</td>
<td>55 (38–86)</td>
<td>M 21</td>
<td>Median 6 (3–22) CT removed when output &lt;400 ml for 2 days</td>
<td>Initially 68% only</td>
<td>Overall 80% (including: 7 requiring bedside TS) Recs: 4 (9.7%, retreated with VATS within 4 months but successful in only 2)</td>
<td>2.4%</td>
<td>Relief of dyspnea and control of symptomatic hydrothorax</td>
<td>3–6 months</td>
</tr>
<tr>
<td>Lin</td>
<td>2006</td>
<td>China</td>
<td>VATS + talc (3–5 g) Defects seen but not repaired</td>
<td>26</td>
<td>442 ± 8.5 (32–64)</td>
<td>M 20</td>
<td>4.3 ± 1.5 (3–8) CT removed when output &lt;50 ml/24 h or at least 2–3 days after air leaks sealed</td>
<td>Overall 91%</td>
<td>CR: 14 (58%) PR: 38%</td>
<td>7.6%</td>
<td>CR: complete absence of HH PR: obvious reduction without respiratory symptoms</td>
<td>6 months to 3 years</td>
</tr>
<tr>
<td>Luh</td>
<td>2009</td>
<td>China</td>
<td>VATS + TTI (3 pts) Repair of defects via CT and electrocautery (9 pts)</td>
<td>12</td>
<td>14.6 (5–29)</td>
<td>M 12</td>
<td>Initial success: 8/12 (67%) Addition: tetracycline pleurodesis via CT in 4</td>
<td>50%a</td>
<td>Symptom improvement and no fluid reaccumulation on the CXR for at least 3 months</td>
<td>20%a</td>
<td>Fever, SBP, hepatorenal syndrome</td>
<td>3 months</td>
</tr>
<tr>
<td>Northup</td>
<td>2009</td>
<td>USA</td>
<td>VATS + talc + mechanical abrasion + peritoneal drain</td>
<td>5</td>
<td>52–79</td>
<td>M 4</td>
<td>12.6 (6–18) Overall 100% CR: 80% PR: 20%</td>
<td>CR resolution of hydrothorax PR: decrease need for thoracentesis</td>
<td>20%a</td>
<td>Fever, SBP, hepatorenal syndrome</td>
<td>3 months</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- **HH**: Hepatic Hydrothorax
- **VATS**: Video-assisted thoracic surgery
- **TTI**: Talcation thoracoscopic instillation
- **CTP**: CT scan
- **CR**: Complete response
- **PR**: Partial response
- **SBP**: Splanchnicus blood pressure
- **MELD**: Model for end-stage liver disease
- **OK–432**: Okilimimanti
- **Lidocaine**: Local anesthetic
- **NS**: Normal saline
- **TIPS**: Transjugular intrahepatic portosystemic shunt
- **Ampule**: Medication vial
- **CXR**: Chest X-ray
- **Failure**: Relapse or recurrent hydrothorax
- **Complications**: Various postoperative complications and infectious complications.
### Table 8 (continued)

<table>
<thead>
<tr>
<th>Author country</th>
<th>Procedure</th>
<th>Total n</th>
<th>Age years</th>
<th>Sex</th>
<th>Duration of drainage in days</th>
<th>Success rate</th>
<th>Success defined</th>
<th>Mortality at 3 months</th>
<th>Complications Follow-up duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helmy [104] 2010 Egypt</td>
<td>Medical thoracoscopy + TS (2–3 g in 50 ml NS) or Vibriamycin (1 g in 50 ml NS) or Poro-iodine (20 ml of 10% in 80 ml NS)</td>
<td>23</td>
<td>20–all R 54±8.1</td>
<td>M 19</td>
<td>9.8±2.3 (4–17)</td>
<td>Overall 75%</td>
<td>Absence of pleural fluid on follow-up CXR</td>
<td>4.3%</td>
<td>Surgical emphysema (18.2%), superficial wound infection (4.5%), mild thoracic pain (4.5%), prehepatic coma (4.5%), tense ascites (10.5%), failure to expand lung immediately after procedure (4.5%) 3 months</td>
</tr>
<tr>
<td>Lee [105] 2011 Korea</td>
<td>VATS 2 pts -Talc (20 g) + bleomycin (30 mg) in 1 pt -Taurolidine (10 g) + Bleomycin (30 mg) in 1 pt Pleurodesis via CT 9 -Talc 3 pts -Taurolidine 2 pts -V. album 6 pts</td>
<td>11</td>
<td>11–all R 63</td>
<td>C 16</td>
<td>Not reported</td>
<td>Overall 72.7%</td>
<td>No longer had dyspnea and CXR did not show pleural effusion at 1 month</td>
<td>50%</td>
<td>Median sessions of pleurodesis (range): 2 (1–3) 16 weeks</td>
</tr>
</tbody>
</table>

| Mean | 174 | 8.7 days | Overall 74.7% | Recs 24.5% | 21.6% | 30.83% |

B = Bilateral; CT = chest tube; CXR = chest X-ray; L = left side; pt(s) = patient(s); R = right side; Rec(s) = recurrence(s); TS = talc slurry; TX = transplant. Age as mean (range) or mean ± SD unless stated as median. Duration of drainage [mean (range)] unless stated as median. a Cumulative mortality during the entire course of the study. b Pleurodesis was repeated with the same agent once in 16 patients and thrice in 4 patients 87.5% of povo-iodine required 2, 75% of Vibramycin 2 and 50% required 3 attempts. Somatostatin was given to all the patients at a dose of 25–50 μg/h, 24 h before the procedure and continued until removal of the chest tube. Mean sessions of pleurodesis (range): 2 (1–3). c Median sessions of pleurodesis (range): 3 (2–10).
had a preoperative INR of 3.1 and a platelet count of 38,000/μl. There was 1 death due to SBP resulting in the hepatorenal syndrome. In another study including a total of 12 patients, 3 underwent VATS with TTI and 9 patients underwent VATS with mechanical abrasion and electrocautery [81]. The initial success rate was 67%. Tetracycline pleurodesis via the chest tube was needed additionally in 4 patients who had fluid drainage >300 ml/day or persistent drainage for >7 days. There were 3 recurrences: 1 was retreated with VATS and 2 with tetracycline pleurodesis via a chest tube.

VATS with Pleurodesis and Repair of Diaphragmatic Defects

VATS also helps in to visualize as well as repair the diaphragmatic defects with fibrin glue or sutures in patients with refractory HH. In a study of 8 patients, diaphragmatic defects were repaired in 6 patients along with VATS and talc pleurodesis [101]. The initial success rate was 75% with a recurrence of 25%. Out of 2 patients in whom defects could not be visualized even after intraperitoneal dye injection, the duration of drainage was longer and pleural effusion recurred in both. Both of these patients died of hepatocellular insufficiency. In another study of 18 patients by Milanez de Campos et al. [80], diaphragmatic defects were seen in 5 patients and repaired in all 5. The success rate increased to 60% from 47.6% after repair of the diaphragmatic defects. The recurrence rate and duration of chest tube drainage was higher in patients in whom the repair of the diaphragmatic defect could not be performed.

In another study, diaphragmatic defects could only be visualized and repaired in 5 of 41 patients [82]: 25 patients were CTP class C and 14 CTP class B. TIPS was not considered in any patient. All patients underwent VATS and talc pleurodesis, with 7 patients requiring bedside talc slurry later on. In a small study from Tokyo [83], VATS was combined with argon beam coagulation of the

Fig. 2. Proposed algorithm for the management of HH.
diaphragm surface followed by covering of the dia-
phragm with a bioabsorable prosthesis and 3 ml of fibrin
glue. The diaphragm surface was then sprinkled with
5KE of OK-432 and 100 mg of minocycline was instilled
into the thoracic cavity. Diaphragmatic defects were re-
paired in 2 of 9 patients. The initial success rate was 100%
in the study. There were 2 recurrences, 1 was treated with
repeat pleurodesis with improvement and 1 was treated
conservatively because of end-stage hepatocellular carci-
noma.

The most common complications associated with
pleurodesis seen in different studies included fever and
mild thoracic pain, though empyema, septic shock and
hepatic encephalopathy with liver failure have also been
reported. Persistent high volume ascitic drainage from
the chest tube site causing azotemia and renal failure is
another dreaded complication when the chest tube is left
for a prolonged period. Mechanical pleurodesis carries a
high risk of bleeding especially in patients with advanced
liver disease and coagulopathy. The average cumulative
mortality rate in all ten studies was 30.83% and was at-
tributed to hepatocellular insufficiency, hemorrhage due
to esophageal varices, hepatic encephalopathy, septic
shock and renal failure. The average 30-day mortality was
21.6%.

Pleurodesis is an effective method for the management
of refractory HH. Even though most of the studies have
used VATS to achieve pleurodesis with a good overall
success rate, it requires the use of general anesthesia
which carries substantial risks for patients with end-stage
liver disease. In these patients, mechanical thoracoscopy may
be a reasonable option for symptom relief. It is done un-
der local anesthesia with conscious sedation. Somatosta-
tin can be combined with pleurodesis to decrease the por-
tosystemic pressure gradient and reaccumulation of pleu-
ral fluid to achieve successful pleurodesis. Paracentesis
performed before pleurodesis may also increase the suc-
cess rate by decreasing ascites and flux of fluid from the
peritoneal to the pleural cavity, allowing more time for
the pleural spaces to be opposed to each other. The PleurX
catheter may also be combined with pleurodesis to avoid
and decrease hospitalization in patients, as shown in a
study with malignant pleural effusion [106].

Conclusion

HH is an uncommon complication of portal hyper-
tension. The pathogenesis involves the migration of fluid
from the peritoneal to the pleural cavity through dia-
phragmatic defects. Patients may be asymptomatic, and
dominating clinical manifestations are liver cirrhosis and
portal hypertension; however, pulmonary symptoms like
dyspnea and respiratory failure can also be encountered.
Diagnosis involves a high index of suspicion in a cirrhot-
ic patient who presents with pleural effusion. Pleural flu-
oid analysis is one of the initial diagnostic steps, with most
effusions being transudative. Medical management with
salt restriction and diuretics is the first line of therapy. All
patients with refractory HH should be referred for liver
transplantation (fig. 2). However, in patients with refrac-
tory hydrothorax awaiting transplantation or those who
are not candidates for transplantation, management be-
comes challenging. In these patients, other treatment
modalities that focus on reducing ascitic fluid formation,
preventing the transfer of ascitic fluid across the dia-
phragm, drainage and obliteration of the pleural space
should be considered. Thoracentesis is the initial modal-
ity of choice in refractory hydrothorax patients who fail
medical therapy. Paracentesis to drain ascites is usually
performed before thoracentesis to prevent the flux of flu-
id from the peritoneum to the pleural space because of
negative intrapleural pressure generated after thoracen-
tesis. When thoracentesis is needed every 2–3 weeks, pa-
tients should be considered for TIPS as a bridge to liver
transplant, provided that they are candidates for TIPS.
TIPS is associated with poor survival in patients with
MELD score >15, CTP class C, age >60 years and a high
pre-TIPS creatinine of 2 mg/dl. In these patients or in
patients who do not respond to TIPS, a comprehensive
treatment approach combining different treatment mo-
dalities should be applied. Obliteration of the pleural
space with pleurodesis is a good option for these patients.
Repair of the diaphragmatic defects, CPAP and the
PleurX catheter can be combined with pleurodesis to in-
crease the success rate. There have not been any com-
parative studies of the effectiveness of TIPS and pleurode-
sis in HH patients. Early diagnosis of HH is important to
establish an appropriate management plan. Both TIPS
and pleurodesis with possible VATS-assisted diaphrag-
matic repair are perhaps the best available therapeutic
modalities for bridging a refractory HH patient to liver
transplantation.
References


